Housing Market Correction: Rates Up, Lack Of Buyers, Cracks Forming In Home Improvement
The housing market, still in its relentless rough patch as mortgage rates continue to climb higher, is deterring buyers from making a move.
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival…
Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection
Cidara Therapeutics Inc (NASDAQ: CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.
FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…
FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…
Novavax Ushers New CEO On Uncertainty Concerns, Says It Needs To Work On Competitive COVID-19 Product
COVID-19 vaccine maker Novavax Inc (NASDAQ: NVAX) shares plunged after it
Can Ross Stores Keep Up With Retail Giants Target And Walmart? We’ll See At Market Close
As retailers continue to report their earnings for the fourth quarter of 2022, investors are waiting for the upcoming earnings report from Ross Stores (NASDAQ: ROST), which is set to issue its fourth quarter results after market close on Tuesday<
Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings
Merck & Co Inc (NYSE:MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen…
Would Tesla Start Paying Dividends If This Happened?
As Tesla Inc (NASDAQ: TSLA)'s valuation continues to soar, doubling from January lows, and investors flock to the electric vehicle maker, some are wondering if the company will finally start paying dividends.
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported a break-even in Q4 FY22 compared to a loss of $(0.32) a year ago and the…